Pieris Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PIRS research report →
About the company
Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin proteins are therapeutic, low-molecular-weight molecules derived from naturally occurring human lipocalins, which are found in blood plasma and other bodily fluids.
- CEO
- Stephen S. Yoder
- IPO
- 2015
- Employees
- 46
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $17.96M
- P/E
- -3.26
- P/S
- 0.00
- P/B
- 0.77
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -56.87%
- ROIC
- 0.00%
- Revenue
- $0 · 0.00%
- Net Income
- $-41,715,000 · -139.27%
- EPS
- $-3.71 · 52.62%
- Op Income
- $0
- FCF YoY
- -130.68%
- 52W High
- $22.32
- 52W Low
- $6.20
- 50D MA
- $16.46
- 200D MA
- $14.03
- Beta
- 0.66
- Avg Volume
- 22.13K
Get TickerSpark's AI analysis on PIRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 12, 24 | GERAGHTY JAMES A | sell | 1 |
| Dec 2, 24 | KIRITSY CHRISTOPHER P | other | 500 |
| Nov 6, 24 | Dellora Investments LP | other | 0 |
| Aug 7, 24 | GERAGHTY JAMES A | buy | 1 |
| Aug 12, 24 | ADAR1 Capital Management, LLC | buy | 2,243 |
| Aug 9, 24 | ADAR1 Capital Management, LLC | buy | 3,000 |
| Aug 12, 24 | ADAR1 Capital Management, LLC | buy | 757 |
| Jul 24, 24 | ADAR1 Capital Management, LLC | other | 0 |
| Jul 24, 24 | ADAR1 Capital Management, LLC | other | 0 |
| Jun 21, 23 | Barbier Ann | other | 40,000 |
Our PIRS coverage
Recent articles, reports, and earnings notes.
No research on PIRS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PIRS report →Similar companies
Peers in the same neighborhood.